Live Breaking News & Updates on Research Alliance President

Lupus Research Alliance Hails Approval of Aurinia s Lupkynis(TM) (voclosporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
News provided by
Share this article
Share this article
NEW YORK, Jan. 22, 2021 /PRNewswire/  The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals Lupkynis
TM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month. ....

United States , Brad Rovin , Kennethm Farber , Lupus Research Alliance Board Of Directors , National Institute Of Diabetes , Lupus Research Alliance , Aurinia Pharmaceuticals Inc , Ohio State University , Drug Administration , Division Of Nephrology , Clinical Research Management , National Institutes Of Health Accelerating Medicines Partnership , National Kidney Foundation , Aurinia Pharmaceuticals , Wexner Medical Center , Aurinia Pharmaceutical , National Kidney , Research Alliance President , Medical Director , Wexner Medical , Protocol Review , Design Sub Committee , Lupus Clinical Investigators Network , Lupus Therapeutics , Lupus Research , National Institutes ,